Overactivity of the dopaminergic system in the brain is considered to be a contributing factor to the development and symptomatology of schizophrenia. Therefore, the GABAergic control of dopamine functions was assessed by disrupting the gene encoding the ␣3 subunit of the GABAA receptor. ␣3 knockout (␣3KO) mice exhibited neither an obvious developmental defect nor apparent morphological brain abnormalities, and there was no evidence for compensatory up-regulation of other major GABA A-receptor subunits. Anxiety-related behavior in the elevated-plus-maze test was undisturbed, and the anxiolytic-like effect of diazepam, which is mediated by ␣2-containing GABAA receptors, was preserved. As a result of the loss of ␣3 GABAA receptors, the GABA-induced whole-cell current recorded from midbrain dopamine neurons was significantly reduced. Spontaneous locomotor activity was slightly elevated in ␣3KO mice. Most notably, prepulse inhibition of the acoustic startle reflex was markedly attenuated in the ␣3KO mice, pointing to a deficit in sensorimotor information processing. This deficit was completely normalized by treatment with the antipsychotic D2-receptor antagonist haloperidol. The amphetamineinduced hyperlocomotion was not altered in ␣3KO mice compared with WT mice. These results suggest that the absence of ␣3-subunit-containing GABAA receptors induces a hyperdopaminergic phenotype, including a severe deficit in sensorimotor gating, a common feature among psychiatric conditions, including schizophrenia. Hence, agonists acting at ␣3-containing GABAA receptors may constitute an avenue for an effective treatment of sensorimotor-gating deficits in various psychiatric conditions. haloperidol ͉ sensorimotor gating